JAZZ
Jazz Pharmaceuticals plc
$243.82
-3.09 (-1.25%)
At close · Jul 10
Market Cap
$15.30B
Shares
62,742,820
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$4.27B
+4.9%
FY2025
Net Income
-$356.15M
-163.6%
FY2025
Operating Margin
-10.08%
-27.7pp
FY2025
Diluted EPS
-$5.84
-167.5%
FY2025
Operating Cash Flow
$1.36B
-2.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $4.25B – $4.5B | $4.44B | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B | $2.36B | $2.16B | $1.89B | $1.62B | $1.49B | $1.32B | $1.17B | $872.42M | $585.98M | $272.28M | $173.78M | $128.45M | |
| — | $798.04M | $782.74M | $884M | $849.66M | $590.45M | $505.75M | $335.38M | $299.73M | $226.62M | $198.44M | $162.3M | $135.25M | $85.18M | $41.63M | $20.48M | $14.12M | $25.61M | $36.56M | |
| — | $1.65B | $1.81B | $1.39B | $1.34B | $1.42B | $1.45B | $854.23M | $736.94M | $683.53M | $544.16M | $502.89M | $449.12M | $406.11M | $304.3M | $223.88M | $108.94M | $69M | $58.65M | |
| — | $672.56M | $654.66M | $627.31M | $608.28M | $599.17M | $525.77M | $259.58M | $354.81M | $201.5M | $152.07M | $101.99M | $98.16M | $126.58M | $79.04M | $72.92M | $7.45M | $7.83M | $7.67M | |
| — | — | $41.6M | $32.8M | $30.4M | $30.3M | $26.7M | $18.7M | $15.3M | $15.2M | $13.1M | $11.8M | $9.9M | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | $1.64M | $1.94M | $1.46M | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | $1.28B | $1.09B | $896.32M | $816.58M | $977.29M | $532.11M | $388.14M | $144.45M | $115.99M | $112.52M | |
| — | $4.48B | $4.7B | $3.35B | $3.26B | $3.72B | $2.92B | $1.99B | $1.63B | $1.28B | $1.09B | — | — | — | — | — | — | — | — | |
| — | -$37.74M | -$430.24M | $716.63M | $578.58M | -$65.53M | $170.28M | $378.07M | $532.37M | $614.84M | $528.84M | $591.65M | $508.22M | $195.59M | $340.31M | $197.84M | $127.83M | $57.79M | $15.93M | |
| — | — | -10.08% | 17.61% | 15.09% | -1.79% | 5.5% | 16% | 24.63% | 32.52% | 32.67% | 39.76% | 38.36% | 16.68% | 39.01% | 33.76% | 46.95% | 33.25% | 12.4% | |
| — | — | -$388.64M | $749.43M | $608.98M | -$35.23M | $196.98M | $396.77M | $547.67M | $630.04M | $541.94M | $603.45M | $518.12M | — | — | — | — | — | — | |
| — | $956K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $1.68M | $12.73M | $22.8M | |
| — | $81.6M | $85.8M | $106.3M | $65.1M | $11.5M | $1.8M | $11.1M | $20.5M | $16.9M | $4.1M | — | — | — | — | — | $75K | $4000 | $30K | |
| — | — | — | — | — | — | — | — | — | — | — | — | $1.45M | $8.68M | -$1.7M | — | — | — | — | |
| — | -$232K | -$732K | -$1.66M | -$3.01M | -$9.92M | -$714K | -$2.96M | -$4.09M | -$2.2M | -$1.01M | -$379K | $0 | $0 | — | — | — | — | — | |
| — | -$218.86M | -$627.86M | $470.35M | $297.93M | -$372.78M | -$112.84M | $275.1M | $454.3M | $529.46M | $441.12M | $532.45M | $435.93M | $151.56M | $307.95M | $177.36M | $124.98M | $32.78M | — | |
| — | -$248.54M | -$272.44M | -$91.43M | -$119.91M | -$158.65M | $216.12M | $33.52M | -$73.15M | $80.16M | -$47.74M | $135.24M | $106.4M | $94.23M | $91.64M | -$83.79M | $0 | $0 | — | |
| — | $29.45M | -$356.15M | $560.12M | $414.83M | -$224.06M | -$329.67M | $238.62M | $523.37M | $447.1M | $487.85M | $396.83M | $329.54M | $58.39M | $216.31M | $288.59M | $124.98M | $32.78M | -$6.84M | |
| — | — | -8.35% | 13.77% | 10.82% | -6.12% | -10.65% | 10.1% | 24.21% | 23.64% | 30.14% | 26.67% | 24.87% | 4.98% | 24.79% | 49.25% | 45.9% | 18.86% | -5.32% | |
| — | — | — | — | — | — | — | — | — | — | $0 | $0 | -$1000 | -$1.06M | $0 | $0 | — | — | — | |
| — | $164.12M | $22.92M | $454.6M | $698.19M | -$949.21M | -$595.68M | $327.66M | $497.77M | $390.13M | $664.3M | $346.97M | $184.16M | -$119.86M | $241.42M | $319.66M | $124.95M | $32.78M | -$6.84M | |
| USD/shares | — | — | -$5.84 | $9.06 | $6.55 | -$3.58 | -$5.52 | $4.28 | $9.22 | $7.45 | $8.13 | $6.56 | $5.38 | $0.98 | $3.71 | $5.09 | $3.01 | $0.90 | -$0.23 |
| USD/shares | — | — | -$5.84 | $8.65 | $6.10 | -$3.58 | -$5.52 | $4.22 | $9.09 | $7.30 | $7.96 | $6.41 | $5.23 | $0.93 | $3.51 | $4.79 | $2.67 | $0.83 | -$0.23 |
| shares | — | — | 60.98M | 61.84M | 63.29M | 62.54M | 59.69M | 55.71M | 56.75M | 59.98M | 60.02M | 60.5M | 61.23M | 59.75M | 58.3M | 56.64M | 41.5M | 36.34M | 30.02M |
| shares | — | — | 60.98M | 66.01M | 72.07M | 62.54M | 59.69M | 56.52M | 57.55M | 61.22M | 61.32M | 61.87M | 63.04M | 62.61M | 61.57M | 60.2M | 46.8M | 39.41M | 30.02M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2011–FY2025: $2.3B in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
4.24×
Biotechnology median 8.05×
EV/EBIT
—
Biotechnology median 25.73×
P/E (TTM)
2,216.55×
Biotechnology median 7.68×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| United States | $3,831,598,000 | $3,660,109,000 | $3,489,977,000 | $3,370,379,000 | $2,820,242,000 | $2,144,541,000 | $1,964,161,000 | $1,727,576,000 |
| Europe | $341,122,000 | $312,706,000 | $269,243,000 | $239,638,000 | $230,158,000 | $175,208,000 | $150,201,000 | $125,911,000 |
| Other Countries | $94,866,000 | $96,135,000 | $74,984,000 | $49,357,000 | $43,838,000 | $43,818,000 | $47,399,000 | $37,435,000 |
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Product And Services Product Sales Net Of Deductions | $4,021,849,000 | $3,821,164,000 | $3,736,943,000 | $3,641,429,000 | $3,079,001,000 | $2,346,660,000 | $2,135,601,000 | $1,869,473,000 |
| Total Neuroscience | $2,878,494,000 | $2,698,318,000 | $2,707,843,000 | $2,760,945,000 | — | — | — | — |
| Xywav | $1,656,986,000 | $1,473,202,000 | $1,272,977,000 | $958,425,000 | $535,297,000 | $15,264,000 | $0 | $0 |
| Total Oncology | $1,129,183,000 | $1,111,375,000 | $1,015,254,000 | $873,841,000 | — | — | — | — |
| Epidiolex (Epidyolex) | $1,059,197,000 | $972,423,000 | $845,468,000 | $736,398,000 | $463,645,000 | $0 | $0 | — |
| Rylaze (Enrylaze) | $402,920,000 | $410,846,000 | $394,226,000 | $281,659,000 | — | — | — | — |
| Zepzelca | $307,309,000 | $320,318,000 | $289,533,000 | $269,912,000 | $246,808,000 | $90,380,000 | $0 | $0 |
| Product And Services Royalties And Contract Revenue | $245,737,000 | $247,786,000 | $97,261,000 | $17,945,000 | $15,237,000 | $16,907,000 | $26,160,000 | $21,449,000 |
| High Sodium AG Oxybate Product Royalty Revenue | $211,725,000 | $217,575,000 | $75,918,000 | $0 | $0 | — | — | — |
| Defitelio (Defibrotide) | $199,392,000 | $216,565,000 | $184,000,000 | $194,290,000 | $197,931,000 | $195,842,000 | $172,938,000 | $149,448,000 |
| Vyxeos | $146,709,000 | $162,595,000 | $147,495,000 | $127,980,000 | $134,060,000 | $121,105,000 | $121,407,000 | $100,835,000 |
| Xyrem | $146,034,000 | $233,816,000 | $569,730,000 | $1,020,453,000 | $1,265,830,000 | $1,741,758,000 | $1,642,525,000 | $1,404,866,000 |
| Modeyso | $48,043,000 | $0 | $0 | — | — | — | — | — |
| Other Royalties and Contract Revenue | $34,012,000 | $30,211,000 | $21,343,000 | $17,945,000 | — | — | — | — |
| Ziihera | $24,810,000 | $1,051,000 | $0 | $0 | — | — | — | — |
| Sativex | $16,277,000 | $18,877,000 | $19,668,000 | $16,825,000 | $12,707,000 | $0 | $0 | — |
| Other Products | $14,172,000 | $11,471,000 | $13,846,000 | $6,643,000 | $9,798,000 | $6,842,000 | $17,552,000 | $39,585,000 |
| Erwinaze and Erwinase | — | — | $0 | $0 | $69,382,000 | $147,136,000 | $177,465,000 | $174,739,000 |
| Neuroscience | — | — | $2,707,843,000 | $2,760,945,000 | $2,335,393,000 | $1,785,355,000 | $1,646,239,000 | $1,404,866,000 |
| Oncology | — | — | $1,015,254,000 | $873,841,000 | $733,810,000 | $554,463,000 | $471,810,000 | $425,022,000 |
| Product And Services Other Royalties And Contract Revenue | — | — | $21,343,000 | $17,945,000 | $15,237,000 | — | — | — |
| Product And Services Product Sales | — | — | — | — | — | — | $2,135,601,000 | $1,869,473,000 |
| Rylaze | — | — | $394,226,000 | $281,659,000 | $85,629,000 | $0 | $0 | — |
| Sunosi | — | $0 | $0 | $28,844,000 | $57,914,000 | $28,333,000 | $3,714,000 | $0 |
| Total Oxybate | — | — | — | $1,978,878,000 | $1,801,127,000 | $1,757,022,000 | $1,642,525,000 | $1,404,866,000 |
Key facts
CIK
1232524
CUSIP
G50871105
13F (30d)
39 filings
20 filers
Visit website
Investor relations